My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 2352

    1.

    Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.

    Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA.

    Diabetes Care. 2001 Apr;24(4):710-9.PMID: 11315836 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.

    Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA.

    J Clin Endocrinol Metab. 2002 Jun;87(6):2784-91.PMID: 12050251 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes.

    Miyazaki Y, Matsuda M, DeFronzo RA.

    Diabetes Care. 2002 Mar;25(3):517-23.PMID: 11874940 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.

    Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA.

    Diabetes. 2003 Jun;52(6):1364-70.PMID: 12765945 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.

    Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA.

    J Clin Endocrinol Metab. 2004 Jan;89(1):200-6.PMID: 14715850 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients.

    Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA.

    Diabetologia. 2001 Dec;44(12):2210-9.PMID: 11793023 [PubMed - indexed for MEDLINE]Related articles

    7.

    Bromocriptine: a novel approach to the treatment of type 2 diabetes.

    Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V, Pipek R, Iozzo P, Lancaster JL, Cincotta AH, DeFronzo RA.

    Diabetes Care. 2000 Aug;23(8):1154-61.PMID: 10937514 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.

    Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA.

    J Clin Endocrinol Metab. 2004 Sep;89(9):4312-9.PMID: 15356026 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.

    Miyazaki Y, He H, Mandarino LJ, DeFronzo RA.

    Diabetes. 2003 Aug;52(8):1943-50.PMID: 12882909 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.

    Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE; Pioglitazone 026 Study Group.

    Coron Artery Dis. 2001 Aug;12(5):413-23.PMID: 11491207 [PubMed - indexed for MEDLINE]Related articles

    11.

    Improved insulin action and glycemic control after long-term angiotensin-converting enzyme inhibition in subjects with arterial hypertension and type II diabetes.

    Torlone E, Britta M, Rambotti AM, Perriello G, Santeusanio F, Brunetti P, Bolli GB.

    Diabetes Care. 1993 Oct;16(10):1347-55.PMID: 8269792 [PubMed - indexed for MEDLINE]Related articles

    12.

    The effect of pioglitazone on the liver: role of adiponectin.

    Gastaldelli A, Miyazaki Y, Mahankali A, Berria R, Pettiti M, Buzzigoli E, Ferrannini E, DeFronzo RA.

    Diabetes Care. 2006 Oct;29(10):2275-81.PMID: 17003306 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.

    Frias JP, Yu JG, Kruszynska YT, Olefsky JM.

    Diabetes Care. 2000 Jan;23(1):64-9.PMID: 10857970 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.

    Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL.

    Clin Ther. 2000 Dec;22(12):1395-409.PMID: 11192132 [PubMed - indexed for MEDLINE]Related articles

    15.

    Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.

    Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI.

    Ann Intern Med. 1998 Feb 1;128(3):176-85.PMID: 9454525 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

    Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

    Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483. PMID: 16861090 [PubMed - indexed for MEDLINE]Related articles

    17.

    Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content.

    Ravikumar B, Gerrard J, Dalla Man C, Firbank MJ, Lane A, English PT, Cobelli C, Taylor R.

    Diabetes. 2008 Sep;57(9):2288-95. Epub 2008 Jun 5.PMID: 18535187 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.

    Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL.

    Am J Med. 2001 Jul;111(1):10-7.PMID: 11448655 [PubMed - indexed for MEDLINE]Related articles

    19.

    Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.

    Miyazaki Y, DeFronzo RA.

    Diabetes Obes Metab. 2008 Dec;10(12):1204-11. Epub 2008 May 12.PMID: 18476983 [PubMed - indexed for MEDLINE]Related articles

    20.

    Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.

    Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G, Ciccarelli L, Piccinni MN.

    Clin Ther. 2004 May;26(5):744-54.PMID: 15220018 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity